Barinthus Biotherapeutics plc (NASDAQ:BRNS) Sees Significant Increase in Short Interest

Barinthus Biotherapeutics plc (NASDAQ:BRNS) saw a significant growth in short interest during the month of November. As of November 15th, there was short interest totalling 11,700 shares, a growth of 39.3% from the October 31st total of 8,400 shares. Approximately 0.0% of the company’s stock are sold short. Based on an average daily volume of 45,300 shares, the short-interest ratio is currently 0.3 days.

Barinthus Biotherapeutics Price Performance

Barinthus Biotherapeutics stock traded up $0.03 during midday trading on Friday, reaching $0.99. The company’s stock had a trading volume of 132,074 shares, compared to its average volume of 74,560. Barinthus Biotherapeutics has a fifty-two week low of $0.81 and a fifty-two week high of $4.16. The stock’s 50 day simple moving average is $1.23 and its 200 day simple moving average is $1.44.

Barinthus Biotherapeutics (NASDAQ:BRNS) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.23. The firm had revenue of $14.97 million for the quarter. During the same period in the previous year, the business earned ($0.37) earnings per share. As a group, analysts predict that Barinthus Biotherapeutics will post -1.52 earnings per share for the current fiscal year.

Analysts Set New Price Targets

BRNS has been the topic of several recent analyst reports. Alliance Global Partners dropped their price target on shares of Barinthus Biotherapeutics from $11.00 to $9.50 and set a “buy” rating on the stock in a research note on Tuesday, August 13th. HC Wainwright restated a “buy” rating and set a $5.00 target price on shares of Barinthus Biotherapeutics in a research report on Tuesday, November 19th.

Institutional Trading of Barinthus Biotherapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BRNS. M&G Plc purchased a new stake in Barinthus Biotherapeutics in the 2nd quarter valued at about $7,276,000. Alphabet Inc. purchased a new stake in shares of Barinthus Biotherapeutics during the 2nd quarter worth about $2,119,000. Ipswich Investment Management Co. Inc. purchased a new stake in shares of Barinthus Biotherapeutics during the 2nd quarter worth about $32,000. Finally, Catalina Capital Group LLC purchased a new stake in shares of Barinthus Biotherapeutics during the 2nd quarter worth about $25,000. Hedge funds and other institutional investors own 25.20% of the company’s stock.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.